(-0.74%) 5 069.75 points
(-0.23%) 38 591 points
(-1.33%) 17 429 points
(0.18%) $82.96
(-0.42%) $1.646
(-0.33%) $2 330.70
(-0.52%) $27.21
(-0.47%) $911.50
(-0.18%) $0.933
(-0.18%) $10.96
(-0.21%) $0.801
(0.17%) $92.48
Quarter results tomorrow
(bmo 2024-04-26)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments...
Stats | |
---|---|
Today's Volume | 10 430.00 |
Average Volume | 18 736.00 |
Market Cap | 765.85M |
EPS | PLN-0.130 ( 2023-11-22 ) |
Next earnings date | ( PLN0 ) 2024-04-26 |
Last Dividend | PLN0.0900 ( 2023-06-29 ) |
Next Dividend | PLN0 ( N/A ) |
P/E | -30.00 |
ATR14 | PLN0.0630 (0.41%) |
Volume Correlation
Celon Pharma S.A. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Celon Pharma S.A. Correlation - Currency/Commodity
Celon Pharma S.A. Financials
Annual | 2022 |
Revenue: | PLN161.92M |
Gross Profit: | PLN95.45M (58.95 %) |
EPS: | PLN-0.770 |
Q3 | 2023 |
Revenue: | PLN42.50M |
Gross Profit: | PLN26.17M (61.58 %) |
EPS: | PLN-0.130 |
Q2 | 2023 |
Revenue: | PLN42.23M |
Gross Profit: | PLN26.06M (61.71 %) |
EPS: | PLN0.180 |
Q1 | 2023 |
Revenue: | PLN39.01M |
Gross Profit: | PLN22.70M (58.20 %) |
EPS: | PLN-0.190 |
Financial Reports:
No articles found.
Celon Pharma S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
PLN0 (N/A) |
PLN0 (N/A) |
PLN0 (N/A) |
PLN0.0900 (N/A) |
PLN0 (N/A) |
PLN0 (N/A) |
PLN0 (N/A) |
PLN0 (N/A) |
PLN0 (N/A) |
PLN0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | PLN0.170 | 2017-05-31 |
Last Dividend | PLN0.0900 | 2023-06-29 |
Next Dividend | PLN0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 7 | -- |
Total Paid Out | PLN1.110 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.27 | -- |
Div. Sustainability Score | 4.52 | |
Div.Growth Potential Score | 0.137 | |
Div. Directional Score | 2.33 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VRC.WA | Ex Dividend Knight | 2023-08-29 | Monthly | 0 | 0.00% | |
GPP.WA | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
R22.WA | Ex Dividend Junior | 2023-08-29 | Annually | 0 | 0.00% | |
COG.WA | Ex Dividend Junior | 2023-05-04 | Sporadic | 0 | 0.00% | |
OEX.WA | Ex Dividend Junior | 2023-07-06 | Sporadic | 0 | 0.00% | |
BHW.WA | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
LSI.WA | Ex Dividend Junior | 2023-08-16 | Sporadic | 0 | 0.00% | |
ASB.WA | Ex Dividend Knight | 2023-06-23 | Semi-Annually | 0 | 0.00% | |
IFI.WA | Ex Dividend Knight | 2023-09-06 | Quarterly | 0 | 0.00% | |
WWL.WA | Ex Dividend Knight | 2023-07-13 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.114 | 1.500 | -2.28 | -3.42 | [0 - 0.5] |
returnOnAssetsTTM | -0.0333 | 1.200 | -1.109 | -1.331 | [0 - 0.3] |
returnOnEquityTTM | -0.0408 | 1.500 | -1.565 | -2.35 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.744 | 0.800 | 6.28 | 5.02 | [1 - 3] |
quickRatioTTM | 1.438 | 0.800 | 6.25 | 5.00 | [0.8 - 2.5] |
cashRatioTTM | 0.215 | 1.500 | 9.92 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0289 | -1.500 | 9.52 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -5.95 | 1.000 | -3.31 | -3.31 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.133 | 2.00 | 9.96 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.605 | 2.00 | -0.303 | -0.605 | [0 - 20] |
debtEquityRatioTTM | 0.0361 | -1.500 | 9.86 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.598 | 1.000 | 3.37 | 3.37 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0936 | 1.000 | -3.87 | -3.87 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.407 | 1.000 | 8.85 | 8.85 | [0.2 - 2] |
assetTurnoverTTM | 0.292 | 0.800 | -1.386 | -1.109 | [0.5 - 2] |
Total Score | 4.52 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -40.72 | 1.000 | -4.21 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0408 | 2.50 | -1.006 | -2.35 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.605 | 2.00 | -0.202 | -0.605 | [0 - 30] |
dividendYielPercentageTTM | 0.590 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.133 | 2.00 | 9.96 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.524 | 1.500 | -6.82 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0403 | 1.000 | -1.493 | 0 | [0.1 - 0.5] |
Total Score | 0.137 |
Celon Pharma S.A.
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators